Phenytoin

Small molecule

Approved / Phase 4Voltage-gated sodium channelsNo featureable registry evidence
Approvedregulatory verdict

Evidence outlook

Approved: Epilepsy

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Every registered study for this drug was reviewed, and none was selected as featured evidence for its approved use, so its Featured trials section is empty.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (4)
Epilepsy
NCT04573803 · Cambridge University Hospitals NHS Foundation Trust
2021-03-01 – 2028-03-01 · Traumatic Brain Injury, Post Traumatic Seizures
What this study did
Other / comorbidity
NCT02374567 · Hannover Medical School
2015-01 – 2017-06-28 · Dementia, Depression, Schizophrenia, Psychosomatic Disorders, Anxiety Disorders
What this study did
NCT00781196 · All India Institute of Medical Sciences
2008-05 – 2009-07 · Gingival Overgrowth
What this study did
NCT00591006 · University of Texas Southwestern Medical Center
2008-01 – 2009-07 · Healthy
What this study did
Phase 2/3 (3)
Other / comorbidity
NCT07590375 · Cairo University
2026-06-01 – 2027-10 · Gingival Recession
What this study did
NCT04647877 · David J. Kopsky
2020-09-17 – 2023-06-15 · Chronic Idiopathic Axonal Polyneuropathy
What this study did
NCT03512756 · Tyme, Inc
2018-03-27 – 2021-12-28 · Pancreatic Cancer
What this study did
Phase 2 (6)
Other / comorbidity
NCT02939937 · Tehran University of Medical Sciences
2017-03-09 – 2019-01-02 · Optic Neuritis
What this study did
NCT01730313 · Centers for Disease Control and Prevention
2016-02 – 2017-07 · Nodding Syndrome
What this study did
NCT02413658 · Children's Surgical Center, Cambodia
2015-03 – 2016-04 · Wound, Re-Epithelialization
What this study did
NCT01451593 · University College, London
2011-11 – 2015-03 · Optic Neuritis, Multiple Sclerosis
What this study did
NCT01187719 · Radboud University Medical Center
2010-05 – 2012-09 · HIV-infection, Pregnancy, Mother to Child Transmission
What this study did
NCT00040469 · Baylor College of Medicine
2000-08 – 2003-11-21 · Sickle Cell Anemia, Hemoglobinopathy, Thalassemia
What this study did
Phase 1/2 (2)
Other / comorbidity
NCT00245037 · OHSU Knight Cancer Institute
2005-06 – 2015-08 · Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition
What this study did
NCT00801931 · Columbia University
2007-09-06 – 2009-05-05 · Leukemia, Lymphoma, Neuroblastoma, Immunodeficiencies, Anemia
What this study did
Phase 1 (25)
Epilepsy
NCT02707965 · Food and Drug Administration (FDA)
2017-06-08 – 2018-09-04 · Epilepsy
What this study did
NCT00627575 · GlaxoSmithKline
2008-02-04 – 2008-09-12 · Epilepsy
What this study did
NCT02283827 · Bial - Portela C S.A.
2007-01 – 2007-03 · Epilepsy
What this study did
Other / comorbidity
NCT07890428 · Misr University for Science and Technology
2026-10-20 – 2027-01-20 · Oral Ulcer, Oral Mucositis, Aphthous Stomatitis
What this study did
NCT07066722 · ViiV Healthcare
2025-07-07 – 2025-12-17 · HIV Infections
What this study did
NCT06919991 · Arcus Biosciences, Inc.
2025-05-02 – 2025-10-18 · Healthy Participants
What this study did
NCT06906809 · BeiGene
2025-04-03 – 2025-10-13 · Healthy Volunteers
What this study did
NCT06903715 · Merck Sharp & Dohme LLC
2025-03-28 – 2025-05-27 · Healthy
What this study did
NCT07824193 · Epygenix
2025-01-15 – 2025-04-03 · Drug Drug Interaction
What this study did
NCT06543043 · BeiGene
2024-08-19 – 2024-11-07 · Not Determined
What this study did
NCT06466473 · Pfizer
2024-07-03 – 2024-10-04 · Healthy
What this study did
NCT06379958 · Modern Biosciences Ltd
2024-04-08 – 2024-09-30 · Pharmacokinetics
What this study did
NCT06719557 · Merck Sharp & Dohme LLC
2024-05-20 – 2024-07-30 · Healthy
What this study did
NCT05901714 · Bristol-Myers Squibb
2023-06-14 – 2024-04-11 · Healthy Participants
What this study did
NCT06633185 · Mansoura University
2022-01-01 – 2023-01-01 · Anal Fissure Chronic, Anal Fissure, Wound Healing
What this study did
NCT04956627 · Bristol-Myers Squibb
2021-07-28 – 2022-04-27 · Healthy Participants
What this study did
NCT04845646 · Gannex Pharma Co., Ltd.
2021-03-16 – 2021-06-10 · Healthy, NAFLD
What this study did
NCT01680042 · Shahid Beheshti University of Medical Sciences
2012-10 – 2013-03 · Wound Healing, Pain
What this study did
NCT01635829 · Janssen Infectious Diseases BVBA
2012-05 – 2012-09 · Healthy Participants
What this study did
NCT01355068 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2011-05 – 2011-06 · Healthy
What this study did
NCT01122940 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2010-07 – 2010-08 · Healthy
What this study did
NCT01122953 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2010-04 – 2010-06 · Healthy
What this study did
NCT00647621 · Mylan Pharmaceuticals Inc
2005-10 – 2005-12 · Healthy
What this study did
NCT00000285 · National Institute on Drug Abuse (NIDA)
1996-05 – 2001-12 · Cocaine-Related Disorders
What this study did
Phase 4 (13)
Epilepsy
NCT05697614 · Dr Cipto Mangunkusumo General Hospital
2023-03-01 – 2023-06-30 · Drug Resistant Epilepsy
What this study did
NCT04829838 · ayesha tariq
2019-07-25 – 2021-07-26 · Status Epilepticus
What this study did
NCT04967326 · Gia Dinh People Hospital
2016-01-01 – 2018-12-31 · Epilepsy
What this study did
NCT01478035 · M. Carmen Cabellos Minguez
2011-11 – 2015-12 · Seizures, Pneumococcal Meningitis
What this study did
NCT00610532 · Jim McAuley
2006-03 – 2011-06 · Epilepsy
What this study did
NCT00510783 · Emory University
2007-07 – 2008-12 · Tonic-clonic Seizure
What this study did
NCT00219479 · Penn State University
1997-08 – 2007-12 · Seizures
What this study did
Other / comorbidity
NCT06942468 · Assiut University
2025-07-01 – 2027-08-01 · Atrophic Acne Scar
What this study did
NCT02595723 · University of Texas Southwestern Medical Center
2015-07 – 2016-12 · Cognitive Impairment
What this study did
NCT00618436 · University of Cincinnati
2007-08 – 2009-09 · Traumatic Brain Injury, Subarachnoid Hemorrhage
What this study did
NCT00581893 · University of Iowa
2005-08 – 2008-12 · Cognitive Measures, Driving Simulator Performance
What this study did
NCT00366067 · Centre of Chinese Medicine, Georgia
2006-08 – 2007-02 · Bronchial Asthma
What this study did
NCT00146237 · Beersheva Mental Health Center
2003-11 – 2005-01 · Depression
What this study did
Early phase / not applicable (12)
Epilepsy
NCT06067412 · Shaheed Zulfiqar Ali Bhutto Medical University
2022-08-01 – 2023-01-31 · Status Epilepticus
What this study did
NCT00004403 · Johns Hopkins University
2000-05 – 2002-03 · Epilepsy, Cysticercosis
What this study did
Other / comorbidity
NCT07841366 · Al-Azhar University
2025-12-15 – 2026-06-20 · Treatment of Striae Alba
What this study did
NCT07801157 · Mansoura University
2024-07-01 – 2025-12-01 · Postoperative Wound Healing After Oral Cancer Surgery
What this study did
NCT06312254 · Aalborg University
2024-04-09 – 2024-12-11 · Peripheral Neuropathy
What this study did
NCT05542589 · Cairo University
2022-03-01 – 2023-02-15 · Pressure Ulcer
What this study did
NCT00162461 · Hadassah Medical Organization
1998-08 – 2020-12 · Healthy
What this study did
NCT03096522 · Mansoura University
2017-02-20 – 2018-03-30 · Anal Fistula
What this study did
NCT03269214 · Shiraz University of Medical Sciences
2012-09-01 – 2017-03-30 · Osteonecrosis Due to Drugs, Jaw
What this study did
NCT00774306 · Thomas Jefferson University
2009-04 – 2012-06 · Subarachnoid Hemorrhage
What this study did
NCT00226538 · Hadassah Medical Organization
started 1999-08 · Healthy Volunteers
What this study did
NCT00333931 · Michael E. DeBakey VA Medical Center
started 2006-06 · Impulsive Aggression, Posttraumatic Stress Disorder
What this study did
Used as active comparator (8)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (2)
Epilepsy
NCT00210782 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2004-06 – 2007-08 · Epilepsy
What this study did
NCT00004817 · National Institute of Neurological Disorders and Stroke (NINDS)
started 1991-02 · Post-Traumatic Seizure Disorder, Head Injuries
What this study did
Phase 2 (1)
Epilepsy
NCT02088957 · UCB BIOSCIENCES, Inc.
2014-03 – 2014-10 · Nonconvulsive Electrographic Seizures
What this study did
Phase 1 (2)
Epilepsy
NCT00598923 · University of Pennsylvania
2004-11 – 2009-02 · Traumatic Brain Injury, Epilepsy
What this study did
NCT01878578 · Bial - Portela C S.A.
2002-11 – 2003-03 · Epilepsy
What this study did
Phase 4 (3)
Epilepsy
NCT07072624 · All India Institute of Medical Sciences, Jodhpur
2025-07-23 – 2028-03-15 · Seizures, Traumatic Brain Injuries, Traumatic Brain Injury (TBI) Patients
What this study did
NCT04176887 · Tanta University
2019-01-01 – 2020-08-01 · Comparison, the Efficacy of Levetireacetam, Phenytoin, Management of Pediatric Status Epilepticus
What this study did
NCT02409433 · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
2014-08 – 2015-11 · Seizures
What this study did
Appears in other studies (7)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (2)
Epilepsy
NCT05637086 · Mostafa Bahaa
2022-12-20 – 2027-11-20 · Epilepsy
What this study did
Other / comorbidity
NCT03778996 · Sarcoma Oncology Research Center, LLC
2020-01-03 – 2028-03-31 · Sarcoma, Ewing, Sarcoma
What this study did
Phase 1 (3)
Other / comorbidity
NCT07783503 · Novartis Pharmaceuticals
2026-09-02 – 2026-11-15 · Healthy Participants
What this study did
NCT05995249 · Takeda
2023-08-11 – 2023-12-31 · Healthy Volunteers
What this study did
Phase 4 (1)
Other / comorbidity
NCT03161509 · Rambam Health Care Campus
2017-07-01 – 2019-01-01 · Bariatric Surgery Candidate
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT00162474 · Hadassah Medical Organization
2003-09 – 2030-12 · Healthy
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Epilepsy: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Phenytoin: this drugApprovedSmall moleculeVoltage-gated sodium channelsnot yet gradedNo reviewed efficacy summary in this indication
BrivaracetamApprovedSmall moleculeSynaptic vesicle glycoprotein 2A (SV2A)Partial signalNo reviewed efficacy summary in this indication
Cannabidiol (Epidiolex)ApprovedSmall moleculeGPR55 / TRPV1 / adenosine transport (multi-target), cannabinoidPartial signal
NCT02544763: Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration) (Baseline; up to Week 16): GWP42003-P 25 mg/kg/Day -43.36 percent change (IQR -67.8 to -13.6) | GWP42003-P 50 mg/kg/Day -36.55 percent change (IQR -67 to -5.5) vs Placebo -20.08 percent change (IQR -47.1 to 3.1)
NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2)
CarbamazepineApprovedSmall moleculeSodium channelsnot yet gradedNo reviewed efficacy summary in this indication
Cenobamate (Xcopri)ApprovedSmall moleculeSodium channels + GABA-A receptorsWeak signal
NCT03678753: USA and Rest of World (RoW): Percent Change in PGTC Seizure Frequency Per 28 Days During the Double-blind Treatment Period Relative to Baseline. (Baseline and 22-week Double-blind Treatment Period.): Cenobamate -71.9% (range -100 to 273) vs Placebo -39.61% (range -100 to 211.8)
NCT04557085: Median percent change in 28-day focal seizure frequency, 6-week maintenance phase: placebo -25.9% vs cenobamate 100 mg -42.6%, 200 mg -78.3%, 400 mg -100% (all p<.001; Epilepsia 2026)
Clobazam (Onfi)ApprovedSmall moleculeGABA-A receptorReliable signal
NCT00518713: Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100)
NCT01160770: Median Percent Reduction in Average Weekly Rate of Drop Seizures Based on the 7-day Assessment (Baseline to month 36): Clobazam 92.3 percentage of drop seizures (range -588 to 100)
Clobazam (Sympazan)ApprovedSmall moleculeGABA-A receptor (benzodiazepine site)not yet gradedNo reviewed efficacy summary in this indication
Diazepam (Diastat)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Diazepam (Valium)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Diazepam (Valtoco)ApprovedSmall moleculeGABA-A receptorWeak signalFeatured results are non-efficacy only in this race
Divalproex Sodium (Depakote ER)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Eslicarbazepine Acetate (Aptiom)ApprovedSmall moleculeVoltage-gated sodium channelPartial signal
NCT02484001: Primary endpoint (retention time / probability of ESL withdrawal) at 24 months: 0.0638 (95% CI 0.0292-0.1366) in the ESL/ESL group vs 0.0472 (95% CI 0.0180-0.1210) in the CBZ-CR/ESL group
NCT00988156: Change From Baseline in Seizure Frequency (Baseline up to Visit 7): Esl (BIA 2-093) 36.6 seizures/month (Standard Deviation 72.47) vs Placebo 62 seizures/month (Standard Deviation 186.19) missed
EthosuximideApprovedSmall moleculeT-type calcium channelReliable signal
NCT00088452: Freedom from treatment failure at 16–20 weeks: 81/154 ethosuximide vs 43/146 lamotrigine, odds ratio 2.66 (95% CI 1.65–4.28; p<0.001); ethosuximide vs valproic acid: 81/154 vs 85/146, with no direct statistical comparison posted.
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Reliable signal
NCT01713946: Primary 1, response rate (≥50% seizure-frequency reduction) in the maintenance period: placebo 15.1%, low-exposure everolimus 28.2% (p=0.0077), high-exposure everolimus 40.0% (p<0.0001), met for both doses. Primary 2, median percentage reduction in seizure frequency: placebo 14.9%, low exposure 29.3% (p=0.0028), high exposure 39.6% (p<0.0001), met for both doses.
FelbamateApprovedSmall moleculeNMDA receptor (glycine site, antagonist)not yet gradedNo reviewed efficacy summary in this indication
Fenfluramine (Fintepla)ApprovedSmall moleculeSerotonin 5-HT2 receptorsReliable signal
NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966)
FosphenytoinApprovedSmall moleculeVoltage-gated sodium channelPartial signalNo reviewed efficacy summary in this indication
GabapentinApprovedSmall moleculeα2δ subunit of voltage-gated calcium channelsPartial signal
NCT00007670: VA Cooperative Study 428 (18 centers, 593 elderly patients with new-onset seizures), matching this trial's title/sponsor/design exactly. Primary endpoint (12-month trial retention): early-termination rates were gabapentin 51%, lamotrigine 44.2%, carbamazepine 64.5% (p=0.0002); gabapentin significantly outperformed carbamazepine (p=0.008) but was not shown superior to lamotrigine. Seizure control was similar across all three arms.
NCT00603473: Response Ratio of Gabapentin in Japanese Pediatric Patients With Partial Seizures (12 weeks): Gabapentin -0.158 ratio (95% CI -0.221 to -0.096)
GanaxoloneApprovedSmall moleculeGABA-A receptorPartial signal
NCT04391569: Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE (Up to 30 minutes): Ganaxolone 79.59% (95% CI 65.657 to 89.755) vs Placebo 12.77% (95% CI 4.832 to 25.741)
NCT01963208: Double Blind: Cohort 2: Percent Change From Baseline in 28-day Seizure Frequency During Titration + Maintenance Period (Baseline and Week 14): Double Blind: Cohort 2 - Ganaxolone -21.28 Percent change (95% CI -29.6 to -14.29) | Double Blind: Cohort 2 - Placebo -10.25 Percent change (95% CI -20.14 to -1.28) missed
Lacosamide (Vimpat)ApprovedSmall moleculeVoltage-gated sodium channelsReliable signal
NCT00136019: Median % reduction in seizure frequency/28 days: lacosamide 400mg/day -37.3% (p=0.008), 600mg/day -37.8% (p=0.006), vs placebo -20.8%; >=50% responder rates 38.3% (400mg) and 41.2% (600mg) vs 18.3% placebo (p<0.001).
NCT02408523: Primary endpoint, time to second PGTC seizure over 24 weeks: hazard ratio 0.540 (95% CI 0.377 to 0.774), p<0.001, lacosamide vs placebo (CT.gov posted results; 49 vs 76 patients with a second PGTC seizure).
LamotrigineApprovedSmall moleculeVoltage-gated sodium channelWeak signal
NCT00088452: Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy (First 16-20 weeks of double blind therapy): Ethosuximide 81/154 | Lamotrigine 43/146 vs Valproic Acid 85/146 missed
NCT01431976: Number of Participants Who Were Seizure Free as Confirmed by Hyperventilation (HV)-Electroencephalography (EEG) at the End of the Maintenance Phase (MP) (Week 12 of the Maintenance Phase (up to Study Week 50)): Lamotrigine 7/20
Levetiracetam (Elepsia XR)
ApprovedUS marketing discontinued
Small moleculeSynaptic vesicle glycoprotein 2A (SV2A)not yet gradedNo reviewed efficacy summary in this indication
Levetiracetam (Keppra XR)ApprovedSmall moleculeSynaptic vesicle protein 2A (SV2A)Partial signalFeatured results are non-efficacy only in this race
Levetiracetam (Keppra)ApprovedSmall moleculeSynaptic vesicle protein 2A (SV2A)Partial signal
NCT00150709: Percentage Change From Baseline in Partial Onset (Type I) Seizure Frequency Per Week Over Time During the Treatment Period (During the Treatment Period (an average of 2 years), compared to Baseline): N159 PBO/LEV -66.4 percentage of change (IQR -90 to -22.3) | N159 LEV/LEV -47.8 percentage of change (IQR -76.2 to -25.4) | N01010+N151 LEV/LEV -66.4 percentage of change (IQR -93.6 to -5.6)
NCT00615615: Partial-onset seizure frequency per week during the 14-week treatment period (primary endpoint): 26.8% greater reduction with levetiracetam vs placebo (p=0.0002, 95% CI 14.0-37.6%); 50%-responder rate 44.6% (45/101) LEV vs 19.6% (19/97) placebo (p=0.0002).
LorazepamApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Midazolam (Nayzilam)ApprovedSmall moleculeGABA-A receptor, GABA-A receptor (benzodiazepine site)Reliable signal
NCT01390220: Participants Who Met the Criteria for Treatment Success After Administration of the Double-blind Dose in the Comparative Phase (CP) (6 hours): USL261 CP 72/134 vs Placebo CP 23/67
NCT01999777: Number of Participants That Were Seizure-free (6 hours): USL261 17/31 vs Placebo 12/31 missed
Oxcarbazepine (Oxtellar XR)ApprovedSmall moleculeVoltage-gated sodium channelPartial signalFeatured results are non-efficacy only in this race
Oxcarbazepine (Trileptal)ApprovedSmall moleculeVoltage-gated sodium channelWeak signal
NCT00050934: Median absolute change in type 1 (partial) seizure frequency per 24 hours: -2.00 (high-dose oxcarbazepine, 60 mg/kg/day) vs -1.37 (low-dose, 10 mg/kg/day), p=0.043; median percentage reduction 83.33% (high-dose) vs 46.18% (low-dose), p=0.047.
Perampanel (Fycompa)ApprovedSmall moleculeAMPA receptor (antagonist)Weak signal
NCT01393743: Core study: median percent change in PGTC seizure frequency per 28 days, perampanel -76.5% vs placebo -38.4%, median difference -30.8 (95% CI -45.5 to -15.2), p=0.0001; 50% responder rate in maintenance 64.2% vs 39.5%, p=0.0019 (n=81 each) (CT.gov posted results).
NCT00699582: Median percent change in 28-day seizure frequency: placebo -9.7%, perampanel 8 mg -30.5% (p<0.001), 12 mg -17.6% (p=0.011); 50% responder rate 14.7%, 33.3% (p=0.002) and 33.9% (p<0.001) (Study 305, Epilepsia 2013).
Phenobarbital Sodium Injection (Sezaby)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
PregabalinApprovedSmall moleculeα2δ subunit of voltage-gated calcium channelsWeak signal
NCT01747915: Log-transformed (Log) 28-day Seizure Rate for All Primary Generalized Tonic-Clonic (PGTC) Seizures During 12-Week Double-Blind Treatment Phase (Day 1 up to Week 12): Pregabalin 5 mg/kg/Day or 7 mg/kg/Day or 300 mg/Day 1.17 Seizure per 28 days (Standard Error 0.097) | Pregabalin 10 mg/kg/Day or 14 mg/kg/Day or 600 mg/Day 1.13 Seizure per 28 days (Standard Error 0.095) vs Placebo 1.14 Seizure per 28 days (Standard Error 0.098) missed
PrimidoneApprovedSmall molecule—not yet gradedNo reviewed efficacy summary in this indication
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
RufinamideApprovedSmall moleculeVoltage-gated sodium channelPartial signal
NCT00334958: Primary endpoint, median percentage reduction in total partial seizure frequency per 28 days (maintenance phase vs baseline, ITT): rufinamide 23.25% vs placebo 9.80%, p = 0.007 (Biton et al., Epilepsia 2011; CT.gov posts the same medians with no statistical analysis).
StiripentolApprovedSmall moleculeGABA-A receptorWeak signalNo reviewed efficacy summary in this indication
TiagabineApprovedSmall moleculeGABA transporter (uptake carrier)not yet gradedNo reviewed efficacy summary in this indication
Topiramate (Eprontia)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Qudexy XR)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydraseReliable signal
NCT01142193: Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline. (11 weeks): USL255 39.5 Percent Reduction (range -227.3 to 100) | Placebo 21.65 Percent Reduction (range -531.2 to 100)
Topiramate (Topamax Sprinkle)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Topamax)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasePartial signal
NCT00113815: Primary endpoint, median % reduction from baseline in daily partial-onset-seizure rate (video-EEG): topiramate 25 mg/kg 20.4% vs placebo 13.1% (p=0.97); 15 mg/kg dose p=0.97 vs placebo; 5 mg/kg dose p=0.91 vs placebo -- no dose significantly better than placebo. missed
NCT00236756: Topiramate add-on in Lennox-Gastaut syndrome: median percentage reduction from baseline in average monthly seizure rate 14.8% with topiramate versus a -5.1% increase with placebo; a >=50% reduction from baseline in major seizures (drop attacks and tonic-clonic seizures) was reached by 33% of the topiramate group versus 8% of the control group.
Topiramate (Trokendi XR)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Valproate
ApprovedUS marketing discontinued
Small moleculeGABAergic neurotransmissionPartial signal
NCT00004817: Phase III NINDS trial (Temkin et al.): valproate did not reduce early or late post-traumatic seizure rates vs phenytoin control, and showed a trend toward higher mortality (13.4% vs 7.2%). missed
Vigabatrin (Sabril)ApprovedSmall moleculeGABA transaminase (GABA-T)Partial signal
NCT02849457: Cognitive Assessment Scores and Developmental Impact (24 months): Delayed Vigabatrin (Placebo) 83.9 score on a scale ± 17.3 vs Early Vigabatrin 80.9 score on a scale ± 15.6 vs Watchful Waiting (Control Group) 97.3 score on a scale ± 16.9 vs Watchful Waiting (Open Label Vigabatrin) 85.0 score on a scale ± 21.6; p=0.8681 (Delayed Vigabatrin (Placebo) vs Early Vigabatrin) missed
Vigabatrin (Vigafyde)ApprovedSmall moleculeGABA transaminase (GABA-T)not yet gradedNo reviewed efficacy summary in this indication
Zonisamide (Zonegran)ApprovedSmall moleculeVoltage-gated sodium channelsWeak signalFeatured results are non-efficacy only in this race
Zonisamide (Zonisade)ApprovedSmall moleculeVoltage-gated sodium and T-type calcium channelsnot yet gradedNo reviewed efficacy summary in this indication
AzetukalnerPhase 3Small moleculeKv7 potassium channelReliable signal
NCT05614063: Median % reduction in monthly focal seizure frequency at Week 12 (X-TOLE2, double-blind period): 25 mg dose -53.2% vs placebo -10.4%; 15 mg dose -34.5% vs placebo -10.4%
BexicaserinPhase 3Small moleculeSerotonin 5-HT2C receptor (agonist)Partial signal
NCT05364021: Primary endpoint, median percentage change in countable motor seizures over the treatment period: bexicaserin -59.8% (n=35) vs placebo -17.4% (n=9), difference 42.4%, p = .0538 (not statistically significant) (PACIFIC, Epilepsia 2026). missed
CarisbamatePhase 3Small moleculeVoltage-gated sodium channelPartial signal
NCT00425282: Primary endpoint, median percent reduction in partial-onset seizure frequency (double-blind phase vs baseline, ITT): carisbamate 400 mg/day 27.27% (n=191) vs placebo 15.21% (n=183), P = 0.009; carisbamate 200 mg/day 16.44% (n=187), P = 0.678 vs placebo (pre-specified Wilcoxon rank sum tests, EU Clinical Trials Register results).
NCT00433667: Primary endpoint, responder rate (at least 50% reduction in partial-onset seizure frequency, double-blind phase vs baseline): carisbamate 400 mg 23.8% and 200 mg 23.1% vs placebo 21.3%; difference 2.48 points (95% CI -6.04 to 11), P = 0.553 (400 mg) and 1.84 points (95% CI -6.58 to 10.26), P = 0.637 (200 mg) (pre-specified CMH tests, EU Clinical Trials Register results). missed
Clemizole (EPX-100)Phase 3Small moleculeHistamine H1 receptor, Serotonin receptors (5-HT)not yet gradedNo reviewed efficacy summary in this indication
Diazepam (Libervant)Phase 3Small moleculeGABA-A receptorWeak signalFeatured results are safety only in this race
ElsunersenPhase 3RNA / oligonucleotideSCN2A (antisense knockdown)Partial signal
NCT05737784: Part A (randomized 3:1, sham-controlled, 9 patients): 77% placebo-adjusted seizure reduction from baseline (p=0.015) (Praxis, 2026-04-06).
RAP-219Phase 3Small moleculeAMPA receptor (TARP γ8-dependent)Weak signal
NCT06377930: Primary endpoint met: 85.2% of patients achieved ≥30% reduction in long episodes (LEs) from baseline (p<0.0001); 72.0% achieved ≥50% reduction in clinical seizures (p<0.0001)
RelutriginePhase 3Small moleculeVoltage-gated sodium channel (persistent current)not yet gradedNo reviewed efficacy summary in this indication
Staccato AlprazolamPhase 3Small moleculeGABA-A receptorReliable signal
NCT03478982: 1.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8); 2.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8)
VormatriginePhase 3Small moleculeVoltage-gated sodium channel (NaV1.2 / NaV1.6)Partial signal
NCT06999902: Primary success measure (reduction in focal seizure frequency over 12 weeks versus placebo) not met, per Praxis; the secondary 50% responder rate was met. The company disclosed no numbers. missed
YCJ-01Phase 3BotanicalCannabinoids (full-spectrum cannabis extract)not yet gradedNo reviewed efficacy summary in this indication
Cannabidiol (JZP926)Phase 2/3Small moleculeCannabidiol (CBD) modulates multiple targets, including the transient receptor potential vanilloid 1 (TRPV1) and the orphan G-protein-coupled receptor GPR55, cannabinoidnot yet gradedNo reviewed efficacy summary in this indication
OpakalimPhase 2/3Small moleculeKv7 potassium channelWeak signal
NCT06425159: Closed early with 27 subjects: median time to second generalized tonic-clonic seizure 141 days with opakalim vs 47 days with placebo; no formal statistical test reported (Biohaven, 2026-05-26).
ABS-1230Phase 2Small moleculeKCNT1 (KNa1.1/Slack) channelnot yet gradedNo reviewed efficacy summary in this indication
AV078Phase 2Small moleculemTORC1 (mammalian target of rapamycin complex 1) (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
BMB-101Phase 2Small moleculeSerotonin 5-HT2C receptor (biased agonist)not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 62 furthest-along competitors are listed; 11 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Phenytoin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
September 2027 (1)
Phase 2/3Gingival RecessionNot yet recruiting
Est. primary completion 2027-09-01 · NCT07590375 · CT.gov ↗
What to watch

See the full readout calendar ↗